Outsourcing-Pharma presents its latest round up of movements in the pharmaceutical outsourcing sector, including appointments at WuXi, Dishman and Sartorius Stedim.
WuXi PharmaTech has appointed Wei-Min Chang as vice president of operations and general manager of its SynTheAll (STA) manufacturing facility, in the Jinshan chemical industry zone of Shanghai, China.
In addition Eric Gu, who previously held the position, has been appointed vice president of business development for manufacturing services.
Chang has previously worked for Eastbound Synopharma (HK) Holding Co, Taiwan Biotech and Eli Lilly.
Dishman Pharmaceuticals has appointed Nick Green to the newly created position of president, Dishman contract research and manufacturing services (CRAMS).
Prior to joining Dishman Green has worked for Codexis Pharmaceuticals, Shasun Pharma Solutions and Rhodia Pharma Solutions.
Yujing Yang has been appointed as director of purification technologies, North America at Sartorius Stedim Biotech.
Yang has previously worked at GE Healthcare, Pall Corporation the US National Research Council, during which time he has gained knowledge of technologies including Xflow filtration and membrane chromatography.
The Harrison Clinical Research (HCR) Group has appointed Michael Willett as president and managing director of HCRAmerica.
Willett has more than 20 years experience at contract research organisations (CRO) and pharma companies in the US, being involved in more than 400 clinical trials in this time.
Prior to joining HCRAmerica Willett has worked at Advanced Biomedical Research, Bristol-Myers Squibb and Marion Laboratories.
Pierre Liberge has been appointed as senior pathologist at CIT, which is part of the company’s efforts to strengthen in this area.
Liberge has 25 years experience in laboratory animal histopathology at companies including Synthélabo Laboratories and MDS Pharma Services.